SCHEMBL5453129

SCHEMBL5453129

CC1CC1C(=O)Nc1sc2c(c1C(N)=O)CCC(=O)C2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.50
PTPRA P18433 1/20 0.50
FLT3 P36888 3/20 0.49
POLB P06746 2/20 0.47
CASP6 P55212 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
KDM4E B2RXH2 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAPT P10636 3/20 0.46
DUSP3 P51452 1/20 0.46
PTPN5 P54829 1/20 0.46
PTPN11 Q06124 1/20 0.46
ALDH1A1 P00352 6/20 0.45
HPGD P15428 3/20 0.45
TSHR P16473 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MAPK10 P53779 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5444887 0.84 FLT3 (0.70) PTPN1PTPRAFLT3POLBCASP6
SCHEMBL5461038 0.84 FLT3 (0.70) FLT3POLBCASP6TDP1KDM4E
SCHEMBL5451305 0.81 MAPT (0.70) FLT3POLBKDM4EMAPTDUSP3
SCHEMBL5460380 0.81 CFTR (0.60) PTPN1FLT3POLBCASP6TDP1
SCHEMBL5453580 0.80 MAPT (0.56) PTPN1FLT3POLBCASP6TDP1
SCHEMBL18902290 0.79 PTPN1 (0.52) PTPN1PTPRAFLT3KDM4EMEN1
SCHEMBL5445094 0.78 PTPN1 (0.59) PTPN1PTPRAFLT3KDM4EMEN1
SCHEMBL5460515 0.77 AIP (0.69) POLBKDM4EMEN1KMT2AMAPT
SCHEMBL5458434 0.76 PTPN1 (0.55) PTPN1FLT3POLBCASP6TDP1
SCHEMBL5465555 0.74 PTPN1 (0.48) PTPN1PTPRAFLT3KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 PTPN1 2192/4885PTPRA 2633/4885FLT3 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.